Catalyst Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Joel Beatty last night initiated coverage of Catalyst Pharmaceuticals (CPRX) with an Outperform rating and $28 price target ...
Yahoo Finance23d
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome ("LEMS"). "We are pleased that our sub-licensee, DyDo, has launched ...
Benzinga.com10d
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock
It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. Market Capitalization Analysis: Reflecting a smaller scale ...
stocknews12d
3 Niche Healthcare Stocks Tackling Rare Diseases
The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid ...
Fintel on MSN10d
Baird Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Outperform Recommendation
Fintel reports that on February 4, 2025, Baird initiated coverage of Catalyst Pharmaceuticals (NasdaqCM:CPRX) with a ...
Nasdaq10d
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock
It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. Catalyst Pharmaceuticals: A Financial Overview Market ...
abrdn plc Buys New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 484,666 shares of the biopharmaceutical company’s stock ...